Indomo turns a first-line but access-limited in-office dermatology procedure, intralesional corticosteroid injection for inflammatory acne, into an at-home self-administered device (ClearPen), pairing a proprietary microneedle self-injection pen with a modernized triamcinolone acetonide formulation. The wedge is access: intralesional triamcinolone is an American Academy of Dermatology first-line option for inflammatory lesions, yet only about 1 million of roughly 20 million US inflammatory-acne patients receive it, gated by a dermatologist shortage of about one per 28,000 Americans.
Validation is early but credible: a 2025 peer-reviewed comparative study found patient-administered intralesional injection comparable in safety and efficacy to provider-administered, supporting self-administration feasibility (Web); Indomo signed a GMP drug/device manufacturing agreement with Lifecore Biomedical (Web); and the company emerged from stealth in October 2025 with a $25M Series B led by Foresite Capital with Polaris and Atomic (Web). StoryHouse committed $306,928.14 via Fund II into the priced B-1 tranche at a $50M post-money valuation, closing 2025-05-27; per the deal terms, B-1 participation obligates pro rata participation in the data-triggered B-2 tranche (Internal: Deal Terms; Meeting Notes recWpBrp6YLTIiUr9).
The self-injection device market is large and compounding at double digits, but Indomo's near-term prize is the access gap in its own indication: an AAD first-line procedure reaches only about 1 in 20 of the inflammatory-acne patients it is indicated for, bottlenecked by a dermatologist shortage. Timing is favorable as self-administration of injectables (accelerated by the GLP-1 era) becomes a consumer norm.
| Player | Approach | Positioning vs Indomo |
|---|---|---|
| Indomo (ClearPen) | At-home intralesional triamcinolone via proprietary microneedle self-injection pen | Only identified at-home intralesional entrant; Phase 2; $25M raised (Web) |
| In-office intralesional injection | Dermatologist-administered triamcinolone (standard of care) | Effective and first-line, but access-limited to ~1M patients/yr (Web) |
| Topical & oral acne Rx | Retinoids, isotretinoin, antibiotics, topicals | Broad and scaled, but slower onset / systemic side effects for acute inflammatory lesions |
| Teledermatology platforms | Online Rx + topicals (e.g., Hims & Hers, Curology) | Distribution muscle but no injectable device; potential channel, not head-to-head |
Moat: A proprietary microneedle self-injection device plus a modernized triamcinolone formulation and its own regulatory pathway, reinforced by Atomic/Hims-linked consumer distribution; web research surfaced no direct at-home intralesional competitor.
Indomo is pre-revenue and clinical-stage (Internal). External signals are directional: a peer-reviewed feasibility study showed patient-administered intralesional injection comparable to provider-administered (Web), the company secured GMP manufacturing with Lifecore Biomedical (Web), and it raised $25M out of stealth (Web). Per the terms, positive Phase 2 interim data (targeted end of Q1 2026) triggers the B-2 tranche (Internal: Meeting Notes recWpBrp6YLTIiUr9).
Most probable exit is acquisition by a large dermatology / consumer-health pharma or a drug-delivery strategic seeking a differentiated at-home injectable franchise; the Atomic/Hims lineage also keeps a consumer-health rollup in play. Medtech M&A ran hot in 2025 (about $80B through November) (Web), though no direct comparable at-home intralesional exit exists yet, so returns hinge on Indomo defining and owning the category.
He is at about $400K-425K. Gary at Polaris was supportive of making this happen in general, and secondary if necessary. Polaris/Rick could guarantee us access at B-2 to split the difference on the $75K-100K; changes average share price cost from 3%-6% (not a big deal). Told Rick to keep us posted, that we would like as close to $500K as possible but there is flexibility; I think we should do the full $500K even if slightly more weighted towards B-2 pricing given attractiveness of deal and modest difference in blended price. Given inflexibility on the wiring timeline, will need to watch wires come in closely.
Source: Meeting Notes recgPUXJAcumBdwKPSpoke with Goodwin. Thinks that there is $433K available; asked if we would be okay with that amount. I pushed and said $500K was important, but if necessary $433K might be ok, though I would need to discuss with Josh/Matt. Rick shared other options for getting us to $500K (secondaries, waiting on Gaingels/Josh Jones check-size). Confirmed that he would need the capital by May 28: tight but I think doable for us. Plan to reconnect Monday when he has more clarity on other checks he is waiting on to fill out the round.
Source: Meeting Notes rec5NwpaC6oZTevS5$22M round led by Foresite; $75M post. Tranched round: $35M pre-money on a $15M tranche for B-1; B-2 is a $68M pre-money based on positive interim data from Phase 2, which will be the trigger for the tranche (end of Q1 2026). Foresite will do $12M of $22M; remaining $10M split between insiders. Steven Peterson and Hyung Chung involved; Jim's decision at the end of the day; Hyung Chung will be on the board.
Pro rata: participation in B-1 obligates participation in B-2 at the same percentage; 1.47x step up on Series A, further 1.37x step up at B-1 price. Check sizes: Foresite in for $12M; Atomic and Polaris on the $10M. StoryHouse has legal pro rata (currently ~1.72% of the business), so legal pro rata would be about $378K. B-1 will close mid-to-late April; wants a sense of interest by the middle of next week. He'll send docs once out of editing and will fight for our allocation should we want it.
Source: Meeting Notes recWpBrp6YLTIiUr9